Starting TRT without a monitoring plan is like driving cross-country without checking the gauges. Testosterone replacement is safe when properly monitored — the "properly monitored" part does the heavy lifting. Here's the lab schedule that keeps you in the safe lane.
The Monitoring Timeline
Before Starting (Baseline)
Everything measured before the first injection serves as comparison data for everything after. The baseline panel should include: total and free testosterone (two morning draws), SHBG, LH/FSH, estradiol (sensitive assay), CBC with hematocrit, comprehensive metabolic panel, lipid panel, PSA, thyroid panel (TSH, free T4), and prolactin.
LH and FSH at baseline are particularly important — they're the only way to distinguish primary hypogonadism (testicular failure, high LH/FSH) from secondary (pituitary signaling failure, low LH/FSH). Once TRT starts, LH and FSH suppress and this diagnostic window closes.
6 Weeks After Starting (First Check)
The first follow-up panel confirms that TRT is achieving adequate testosterone levels and checks for early hematocrit elevation. Include: total and free testosterone (drawn at trough — the morning before your next injection), hematocrit/hemoglobin (CBC), and estradiol. Six weeks allows testosterone to reach steady state on most protocols.
3 Months (Stabilization Check)
Full panel: testosterone (total/free), estradiol, CBC, CMP, lipids. This is the dose-adjustment checkpoint. If testosterone is below target, dose increases. If hematocrit is trending above 52%, the conversation about dose reduction or blood donation begins. If estradiol is above range with symptoms, management options are discussed.
6 Months and Ongoing
After the first year, most stable TRT patients can shift to every-6-month monitoring if all parameters are in range. The panel: testosterone (total/free), estradiol, CBC, CMP, lipids, PSA. Annual additions: thyroid panel, DEXA (if indicated), and any specialty markers relevant to your broader stack.
The Critical Markers and Their Thresholds
| Marker | Target Range on TRT | Action Threshold |
|---|---|---|
| Total testosterone (trough) | 500–800 ng/dL | Below 400 → increase dose; Above 1000 → reduce dose |
| Free testosterone | Mid-upper normal for age | Adjust based on symptoms + SHBG context |
| Hematocrit | Below 52% | Above 54% → reduce dose, hydrate, consider phlebotomy |
| Estradiol (sensitive) | 20–50 pg/mL (varies) | Above 50 with symptoms → investigate; don't treat by number alone |
| PSA | Age-appropriate; track velocity | Velocity >0.75 ng/mL/year → urology referral |
| Liver enzymes (AST/ALT) | Within reference range | Elevated → investigate cause (oral T, alcohol, supplements) |
Common Mistakes in TRT Monitoring
Drawing at peak instead of trough: Testosterone should be measured at trough (the morning before your next injection) to assess your lowest level. Peak measurements overestimate your average exposure and lead to inappropriate dose reductions.
Treating estradiol by number alone: Some clinicians prescribe aromatase inhibitors (anastrozole) for any estradiol above a threshold, regardless of symptoms. Evidence-based practice treats estradiol only when it's elevated AND causing symptoms (gynecomastia, significant water retention, mood disturbance). Estradiol is important for bone health, cardiovascular function, and libido in men — suppressing it unnecessarily causes harm.
Skipping PSA trending: A single PSA value is less informative than the trend. Establish baseline, measure every 6–12 months, and track velocity. PSA velocity — not absolute value — drives clinical decisions.
The Bottom Line
Monitor the System, Not Just the Symptom
TRT monitoring isn't optional — it's what separates safe hormone optimization from unmonitored self-medication. The first year requires quarterly bloodwork. After stabilization, semi-annual monitoring covers the essentials. Any platform that doesn't mandate regular lab work isn't practicing responsible TRT management.